A bill to amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan and Medicare Advantage organizations offering an MA-PD plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.

This legislation proposes to change how Medicare prescription drug plans manage their formularies, which are the lists of covered medications. If enacted, the bill would require private insurance companies offering Medicare Part D or Medicare Advantage plans to include certain generic drugs and biosimilar biological products on these lists. This aims to ensure that lower-cost alternatives to brand-name medications are more consistently available to seniors and individuals with disabilities who rely on Medicare for their healthcare coverage.

By requiring the inclusion of these generic and biosimilar products, the bill seeks to increase competition within the Medicare drug market and potentially lower out-of-pocket costs for beneficiaries. Currently, insurance sponsors have more discretion over which drugs they choose to cover; this mandate would standardize the availability of specific affordable alternatives across different plans. The bill has been referred to the Senate Committee on Finance for further consideration.